Next week marks our second annual summer break and full office shutdown to encourage #TeamKura to rest, recharge, and spend time with families and loved ones. Before we head out, hear from Allison Hernandez, SPHR, Director of Human Resources, on why she values the time off and flexibility provided by working at Kura. Learn more about our benefits and values at https://lnkd.in/g8KD2aH
Kura Oncology, Inc.
Biotechnology Research
San Diego, California 19,037 followers
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
About us
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- Website
-
http://www.kuraoncology.com
External link for Kura Oncology, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
Locations
-
Primary
Get directions
12730 High Bluff Dr
Suite 400
San Diego, California 92130, US
-
Get directions
2 Seaport Ln
Suite 8A
Boston, Massachusetts 02210, US
Employees at Kura Oncology, Inc.
Updates
-
This past weekend, we presented preclinical data supporting the potential therapeutic utility of menin inhibitors for the treatment of #diabetes at the American Diabetes Association’s 84th Scientific Sessions. Learn more about these new findings and how you can access our presentation in today’s release: https://lnkd.in/gq3gWKH4 #ADASciSessions
-
At Kura, we are proud to support Black in Cancer, an organization that aims to strengthen the network between black people in the cancer space and highlight black excellence in cancer research and medicine. This #Juneteenth, join us in uplifting African American voices in STEM to strengthen our interconnected approach to bringing new innovations to #cancer patients in need. Hear from Kristin Jones, PhD, Senior Director, Medical & Regulatory Writing on our efforts to provide unique opportunities in STEM for under-represented minorities.
-
To the strong individuals who lived with #cancer— your courage fuels our mission that drives us to develop innovative cancer treatments for patients in need. At Kura, our team shares a deep commitment to patients, and we believe that, together, we can make a positive impact. This #NationalCancerSurvivorsMonth, learn more about our commitment to advancing precision medicines to help cancer patients lead better, longer lives: https://lnkd.in/gsDyPTcR
-
We’re honored to build upon our partnership with Life Science Cares San Diego, deepening our shared commitment of making a meaningful impact in the community. Through this contribution, we aim to provide vital support to critically ill patients struggling with food insecurity. We extend our gratitude to Life Science Cares San Diego and Mama's Kitchen for the opportunity to fulfill an immediate need for an important cause that aligns with our mission and values. #KuraintheCommunity #TeamKura
We are thrilled to share that our partnership with Kura Oncology, Inc. continues to blossom as we work together to fight food insecurity. The Kura team is contributing $100,000 towards our #FoodIsMedicine initiative which will be used to support the local nonprofit, Mama's Kitchen, in assisting critically ill individuals throughout San Diego impacted by food insecurity. Their continued partnership helps fuel our mission of bringing hope and support to those in need. To read more about how we are working together to make a difference in the fight against hunger, visit: https://lnkd.in/gEGnhNER
-
-
From its inception, Kura Oncology has been dedicated to realizing the promise of precision medicine to help patients with cancer lead better, longer lives. The people at Kura have made monumental progress in bringing that vision to life for people with acute leukemias through our KOMET clinical trial program. This is only the beginning, as we continue to grow into a fully integrated research, development, and commercial organization. #ziftomenib Learn more: https://lnkd.in/eV5q_ts2
-
Join us at #EHA2024 booth H06 to explore the KOMET clinical development program evaluating ziftomenib, an investigational menin inhibitor, in acute leukemias. KOMET-001: Phase 2 registration-directed trial in patients with R/R NPM1-m AML KOMET-007: Phase 1 combination trial in patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML KOMET-008: Phase 1 combination trial in patients with NPM1-m or KMT2A-r AML KOMET-007 and KOMET-008 are ACTIVELY RECRUITING Learn more: https://lnkd.in/eDjHq4kV #BloodCancers #HematologyResearch
-
-
Visit us at #EHA2024 Booth H06 to discuss our KOMET clinical trials exploring ziftomenib, an investigational menin inhibitor, for newly diagnosed and relapsed/refractory (R/R) NPM1-m or KMT2A-r acute myeloid leukemia (AML). Discover the KOMET clinical trial program: https://lnkd.in/eNNF8bDY
-
When it comes to our people, we strive to bring out the best in each other and ourselves. Together with our DE&I committee, #TeamKura is proud to support the LGBTQ community and is committed to creating and nurturing an inclusive culture of allyship. During #Pride month and always, we celebrate you, for you!
-
-
#NationalCancerSurvivorsDay, June 2, is a day to celebrate life and recognize those who have, or have had, cancer. National Cancer Survivors Day Foundation, Inc. For adults with acute myeloid leukemia (AML), reaching survival milestones is a challenge, especially for those with complex AML genetic alterations, such as relapsed/refractory NPM1-m or KMT2A-r AML. Through our KOMET clinical program, Kura is striving to address these challenges in an effort to help more people with cancer lead better, longer lives. Learn more: https://lnkd.in/eZNhGyDX